Pain & Central Nervous System Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pain & Central Nervous System Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Heart Disease
Study Shows That Developmental Heart Drug Reduces the Risk of Heart Related Deaths, Heart Attacks and Strokes in High-Risk Patients Compared to Current 'Gold Standard' (1)
November 19th, 2007
Results from a landmark clinical trial announced at the American Heart Association meeting and published simultaneously in the New England Journal of Medicine(1), showed that a developmental heart drug called prasugrel, may prevent 19% fewer heart deaths, strokes and heart attacks compared to clopidogrel1 (Plavix(R)), the current 'gold standard' treatment.(2,3) The global trial demonstrated that treatment with prasugrel was shown to be significantly more effective than treatment with clopidogrel in patients who have already suffered a heart attack or have unstable angina, and have had a procedure to reopen their coronary arteries.(1) Prasugrel and clopidogrel are both...
Source: Pain & Central Nervous System Week (2007-11-19)
|
